NCT05945823 2025-12-29Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsTaiho Oncology, Inc.Phase 2 Active not recruiting53 enrolled
NCT06304974 2025-11-17A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaSichuan Baili Pharmaceutical Co., Ltd.Phase 3 Active not recruiting497 enrolled